1 EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease.

Slides:



Advertisements
Similar presentations
Extrapyramidal disorder and movement disorder
Advertisements

MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Evaluation of Movement Disorders
Extrapyramidal diseases. Ⅰ.Formation of basal ganglia *Corpus striatum:/caudate nucleus \ neostriatum \lentiform/putamen nucleus / \lentiform/putamen.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Idiopathic parkinson’s disease (IPD)
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
EXTRAPYRAMIDAL SYSTEM DISORDERS BASAL GANGLION DYSFUNCTION BASAL GANGLION DYSFUNCTION.
Psychiatric drug induced syndromes Dr Jason Ward.
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Parkinson’s Disease By Nik Sanyal.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Basal ganglia & cerebellar pathology
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
931-4 Convergence Insufficiency. History A 73-year old man with known PD for 10 years, complained of horizontal double vision for 18 months. He could.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Dr. Kleyn Department of Geriatric Medicine SVCMC
Movement Disorders General Overview. BASAL GANGLIA CIRCUITRY.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Parkinson’s Disease. Definition Parkinson's disease (PD) is an idiopathic, slowly progressive, neurodegenerative disorder whereby two or more of the following.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
Parkinson’s Disease superKAT :).
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
By Prof. Hanan Hagar Pharmacology unit Medical College.
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
Emergency caused by psychiatric medications side effects  Serotonin syndrome  Neuroleptic malignant syndrome  Extrpyramidal reactions  Emergencies.
ANTIPSYCHOTIC. What do antipsychotics treat?  Psychotic Disorders (Psychosis) Abnormal Thinking and Perceptions Loss of Contact with Reality Delusions.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Movement Disorders K. Zárubová. Movement disorders MD - abnornal involuntary movements dysfunction of basal ganglia (anatomically) dysfunction of extrapyramidal.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Medication Induced Movement Disorders Jacob Alexander July 2012 Rural & Remote Mental Health Service.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
By Prof. Hanan Hagar Pharmacology unit Medical College.
second most common neurodegenerative disorder progressive loss of muscle control trembling of the limbs and head while at rest stiffness, slowness, and.
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
PARKINSON’S DISEASE Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine.
Pathogenesis and pathology of parkinsonism
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
 DEFINITION: It includes all fibers that can influence the motor end plate activity and do not pass in the pyramidal tract.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinson Disease Parkinson disease is an idiopathic, slowly progressive, degenerative disorder characterized by resting tremor, stiffness (rigidity),
MOVEMENT DISORDERS.
Drugs of Anti-Parkinson’s disease
Parkinson's disease KRZYSZTOF NICPOŃ.
EXTRAPYRAMIDAL SYSTEM DISORDERS
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
The Approach to Tremor (with case examples) Praveen Dayalu MD Associate Professor Department of Neurology University of Michigan.
Tremor Domina Petric, MD.
Domina Petric, MD Huntington´s disease.
Drug-induced dyskinesias
Athetosis, dystonia, tics
Drugs for Degenerative Diseases of the Nervous System
Neurodegenerative diseases
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

1 EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease

2 4 types of movements: Voluntary movement Semivoluntary movement (=unvoluntary) Involuntary movement Automatic movement

3

4 Movement disorders = Extrapyramidal disorder Disorder of regulation of voluntary motoric activity without direct influence towards muscle strength, sensibility, or cerebellum.

5 Extrapyramidal disorder Hyperkinetic disorder: abnormal involuntary movements Hypokinetic disorder: reduction of movements. = Movement disorders are caused by dysfunction of basal ganglia

6 Basal ganglia: Caudate nucleus Putamen Globus pallidus Subthalamic nucleus Substantia nigra

7 Diseases & syndrome with abnormal movements: Essential tremor (familial / benign) Parkinsonism Progressive supranuclear palsy Idiopathic torsion dystonia Chorea sydenham Sindroma Gilles de la Tourette Drug-induced movement disorders, etc.

8 Parkinsonism = Parkinson syndrome 1.Primary / Idiopathic = Paralysis agitans = Parkinson disease 2.Secondary/Symptomatic = Causes: - arteriosclerosis - anoxia /cerebral ischemia - drugs - toxic agent - encephalitis etc.

9 Parkinsonism (CON’T) 3. Paraparkinson / Parkinson plus - Wilson disease - Huntington disease - Normotensive Hydrocephalus

10 Parkinson disease = Parkinson idiopathic = Paralysis agitans -Most commonly be found -Middle age to old age

11 Etiology and pathogenesis The certain Etiology is unknown PD is due to cells degeneration  dopamine decreased in substantia nigra

12 ACh DA I DA ACh I ACh i DA

13 Hypotesis: Aging process: dopaminergic neuronal death !!! anti – oxydative-protective mechanism decreased Environmental toxin: - heavy metal (Iron, Zinc, mercury etc) - MPTP Genetic sensitivity Oxydative stress: dopamine reaction  free radicals

14 Pathology Cutting of mid-brain: degeneration & neuronal death which contain melanin in substansia-nigra. Microscopic: In compacta zone: -Most of neuron are loss -Residual : containings Lewy-bodies

15 Lewy bodies in subst.nigra:

16 Clinical findings. Triad of symptoms: - rigidity - tremor - bradikinesis 1.tremor: - pill rolling tremor - during tension !!!, sleep - disappear - resting tremor = Parkinsonian – tremor

17 Clinical findings (Con’t) 2. Rigidity : “cogwheel” phenomenon. 3. Bradikinese 4. Weakness & fatique 5. Dystonia 6. Parkinsonian facies “mask-like” 7. Micrographia 8. Gait: Festinant gait = Parkinsonian gait

18 Clinical findings (con’t) 9. freezing: late stage, suddlenly stop walking 10. Slowly speaking and monotone 11. Eye movements: - lack of blinking - eye movement disturb. - Glabella reflex (+) 12. Pain: paresthesia of limbs

19 Clinical findings (con’t) 13. ANS disturbance: - salivary / excessive sweating -urinary incontinence etc. 14. Saliva !!!  sialorrhea 15. Hypotension  orthostatic hypotension 16. Depression 17. Dementia

20 Gait:

21 Tremor:

22 Rising:

23 Sitting:

24 Hypomimia:

25 Retropulsion:

26 Freezing:

27 Diagnostic procedure Diagnosis is made clinically based on clinical symptoms found EEG examination : may show diffuse slow wave MRI & CT Scan : may show cortical atrophy.

28 Treatment It is considered: due to dopamine deficiency in CNS. 1.Levodopa 2.Anticholinergic drugs: trihexyphenidyl 3.Antihistamine: diphenhydramine 4.Bromocriptine 5.Amantadine 6.Selegiline

29 TH DD L-tyrosine  l-dopa  DA TH: tyrosine hydroxylase DD: dopa-decarboxylase DA located outside vesicles will be catalyzed by enzymes : MAO(monoamine-oxydase) inside the neuron cell COMT(catechol-o-methyl-transferase) outside the neuron cell.

30 b In peripheral : 1.l-dopa  dopamine I dopa-decarboxylase v ^ dopa-decarboxylase inhibitor = carbidopa  sinemet = benserazide  madopar

31 2. l-dopa  dopamine I catechol-O-methyltransferase (COMT) v ^ COMT – inhibitor : - tolcapone - entacapone

32 Prognosis: The prognosis is still poor.

33 Diseases & syndromes with abnormal movements : Essential tremor (familial / benign) Parkinsonism Progressive supranuclear palsy Idiopathic torsion dystonia Chorea sydenham Sindroma Gilles de la Tourette Drug-induced movement disorders, etc.

34 Parkinsonism = Parkinson syndrome 1.Primary/ Idiopathic = Paralysis agitans = Parkinson disease 2.Secondary / Symptomatic = Well known causes : - arteriosclerosis - anoxia / cerebral ischemia - drugs - toxic agents - encephalitis, etc.

35 Parkinsonism (Con’t) 3. Paraparkinson / Parkinson plus - Wilson disease - Huntington disease - Normotensive Hydrocephalus

36 ESSENTIAL TREMOR ESSENTIAL TREMOR “ Familial tremor “ “ Benign tremor “ “ Autosomal dominant “ Begin at teen-agers or young adults

37 Tremor usually affect one or both hands, head and voices, whereas foot is not affected. Neurological assessments show no other abnormality. Despite the longer the tremor the clearer the symptoms, usually it does not disturb,but the patient feels ashamed.

38 Sometimes it disturbs fine and difficult movements, writing and speaking when laryngeal muscle is involved. Consuming small amount of alcohol  temporary improvement is reported, but the mechanism has not been known yet.

39 Treatment -Diazepam 6 – 15 mg per day -Propranolol mg per day -Primidone -Alprazolam -Not responsive: # thalamotomy # thalamic stimulation

40 CHOREA SYDENHAM Affecting children and young adults resulting from complication of streptococcus hemolytic A infection and the possible basic pathological features is arteritis. Approximately 30% of cases occur 2 or 3 months following rheumatoid fever or polyarthritis, the rest without such historys.

41 Onset can be acute or gradually within 4-6 months, can also occur during pregnancy or oral contraceptive users. Symptoms including abnormal chorea movements, sometimes unilaterally in mild cases. Changes of behavior In children may reveal easily to anger and doughty Labile of emotions

42 In 30% of cases involves the heart Treatment: bed rest, sedatives, prophylaxis antibiotics even though without acute rheumatoid fever. Penicillin injection to be continued orally until 20 years of age to prevent staphylococcal infection. The prognosis basically lies on the complication of the heart.

43 Drug-induced movement disorders 1.Parkinsonism 2.Acute dystonia or dyskinesis 3.Akathisia 4.Tardive dyskinesis 5.Neuroleptic malignant syndrome 6.Others.

44 Parkinsonism. Complication of dopamine receptor inhibitor drugs: - phenothiazine - butyrophenone - thioxanthene - metoclopramide

45 Parkinsonism (Con’t) Symptoms : - rigidity - mask-like face - bradykinesis - tremor (seldom) Treatment : - Discontinue the drug - anti-cholinergic drugs (trihexy- phenidyl)

46 Acute dystonia / dyskinesia blepharospasm torticollis facial grimacing following phenothiazine administration. Treatment: Intravenous anti-cholinergic- drug (benztropine 2 mg or diphenhydra- mine 50 mg).

47 Blepharospasm

48 Akathisia Motoric restlessness, compulsion to move or inability to sit still for more than a short period of time, keep standing or walking. Receiving phenothiazine Treatment: - Lowering the dose  if possible - propranolol mg/hari - anticholinergic drugs / benzodiazepines

49 Tardive dyskinesia Repetitive involuntary movements of the mouth, tongue and lips, occasionally accompanied by dystonic posturing or choreoathetotic movements of trunk and limbs. Mostly following administration of neurolep tic, metoclopramide, antihistamines, tri- cyclic antidepressant and chronic alcohol abuse.

50

51 Tardive dyskinesia (Con’t) Tardive dyskinesia (Con’t) Treatment: - Dopamine antagonists : haloperidol - Catecholamine-depleting agents: reserpine, tetrabenazine. - Baclofen - Calcium channel blocking agents - Vitamin E, etc.

52 Neuroleptic malignant syndrome An acute idiosyncratic reaction to - neuroleptic medication due to central dopamine receptor blockade. May also originate from non-neurololeptic drugs: metoclopramide, domperidone, amphetamines, reserpine, tetrabenazine, tricyclic antidepressants with lithium or with MAO inhibitor and withdrawal of anti- parkinsonian medication.

53 Neuroleptic malignant syndrome(Con’t) The use of cocaine and 3.4 methy- lene dioxymethamphetamine (MDMA) = “Ecstasy” Symptoms are usually abrupt in onset, fever, encephalopathy with fluctuating confusion and agitation progressing to coma, labile BP, tachycardia, diaphoresis in association with dystonia and tremor. The couse is often rapid in untreated cases wit deterioration leading to cardiac failure, pulmonary congestion, pneumonia, renal failure and death.

54 Neuroleptic malignant syndrome (Con’t) Treatment: -Discontinue the neuroleptic drugs -Control of body temperature -Monitor the BP, urine, electrolytes, temperature change -Administer bromocriptine mg/day by NGT -Dantrolene sodium i.v and convert to oral as improvement occurs.

55 Others: Levodopa  various abnormal movement is related to dosage. Bromocriptine, anticholinergic drugs, phenytoin, carbamazepine, amphetamine, lithium and oral contraceptive  may also result in chorea ect.